Trevi Therapeutics, Inc. current report, 29 June 2022

Vollständiges Dokument

Business Context and Reporting Period

Trevi Therapeutics, Inc. filed this Form 8-K on June 29, 2022, to report positive results from its Phase 2b/3 PRISM clinical trial for Haduvio (oral nalbuphine ER) in treating prurigo nodularis. The company is an emerging growth company incorporated in Delaware.

Key Financial Metrics

The filing does not provide specific revenue, profit, or cash flow figures for a reporting period. However, it discloses the following liquidity metric:

  • Cash and Investments: Approximately $78 million as of June 30, 2022.

Debt, margins, and other financial metrics are not disclosed in this document.

Material Changes and Clinical Results

The primary material event is the announcement of statistically significant results from the PRISM trial comparing Haduvio monotherapy (n=168) to placebo (n=176) at week 14:

  • Primary Endpoint: 25% of Haduvio subjects achieved a 4-point reduction in WI-NRS compared to 14% of placebo subjects (p=0.0157).
  • Quality of Life: Haduvio showed significantly greater improvements in ItchyQoL scores across symptoms, functional limitations, and emotions (p=0.0002).
  • Lesion Improvement: 55% of Haduvio subjects saw at least a 1-category improvement in the Prurigo Activity Scale (PAS) versus 38% on placebo (p=0.006).

Outlook, Risks, and Safety Profile

Safety and Adverse Events:

  • TEAEs: Treatment-Emergent Adverse Events were more common in the Haduvio group during the titration period (66.1% vs. 31.3% placebo) but similar during the fixed-dose period (48% vs. 45%).
  • Discontinuations: 36.9% for Haduvio vs. 19.3% for placebo over 14 weeks.
  • Serious Adverse Events (SAE): 8 subjects on Haduvio and 6 on placebo experienced SAEs; none were considered treatment-related.
  • Common Side Effects: Nausea, dizziness, headache, and constipation.
Outlook and Next Steps:
  • The company expects to analyze the full dataset and discuss findings with the FDA.
  • Further details on the development pathway are expected later in the year.
Risks:
  • Uncertainties regarding regulatory views, approval timelines, and fast-track designation.
  • Potential impact of the COVID-19 pandemic on clinical operations.
  • Standard forward-looking statement risks regarding business plans and cash runway.

Investor Verification Checklist

  • Verify the $78 million cash position against the most recent 10-Q or 10-K to confirm runway duration.
  • Confirm the FDA's response to the PRISM trial data and the specific requirements for the next development phase.
  • Review the discontinuation rate (36.9%) to assess potential commercial adoption barriers.
  • Monitor for updates on the "development pathway" promised for later in the year.